RxDoctor Payments Data

Veronica Delaney

Family · Loogootee, INNPI 1003457839

Payments from drug & device makers

$787in general payments, 2019–2025

Across 45 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$177
  • Novo Nordisk$133
  • AstraZeneca$116
  • AbbVie$83
  • Amgen$49
  • Novartis$49
  • plus $180 from 7 others

What the payments were for

  • Food & beverage$787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$787 in reported general payments places this provider in the 60th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$3,469
Medicare patients
84
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$61,105
EliquisApixaban53$41,227
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$37,473
JardianceEmpagliflozin44$33,031
MounjaroTirzepatide30$32,305
JanuviaSitagliptin Phosphate23$19,237
TrulicityDulaglutide14$15,144
FarxigaDapagliflozin Propanediol21$14,336
EntrestoSacubitril/Valsartan13$8,438
Repatha SureclickEvolocumab13$8,134
MyrbetriqMirabegron17$7,189
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,532
Doxepin Hcl12$4,355
SynthroidLevothyroxine Sodium32$2,044
Albuterol Sulfate HfaAlbuterol Sulfate96$1,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$133$61,10565 claims
Lilly USA, LLCMounjaro, Trulicity$177$47,44944 claims
GSKTrelegy Ellipta, Anoro Ellipta$37$43,00572 claims
AstraZenecaFarxiga$116$14,33621 claims
NovartisEntresto$49$8,43813 claims
Astellas Pharma US IncMyrbetriq$16$7,18917 claims
AbbVieSynthroid$83$2,04432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,392 family providers in Indiana.

Other family in Loogootee

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →